The disclosure relates to an antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The disclosure also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
